Low-grade glioma (LGG) is a type of brain tumour that typically occurs in early adulthood. LGG patients usually survive a decade or more, although there is a high risk of treatmentrelated complications. Most LGG tumours grow slowly, but some grow fast and these patients have a particularly poor prognosis. To better predict an individual’s prognosis and identify the most effective treatment and management strategies, there is a need to accurately identify these patients and the features responsible.

This project investigates a potential predictor of poor patient survival in LGG. Our preliminary work indicates that patients who have a high level of a protein called dystrophin in their tumours may have a four-fold decrease in survival time. This project will use brain tumour tissue from LGG patients to confirm our findings. Our work could lead to the development of new screening tests for LGG to identify individuals with a particularly poor prognosis and to better improve the management of the disease for these individuals.